تعليقThe recommendations part of this chapter has eight sections that cover aspects of the treatment of DR-TB. The aspects covered are:
- Treatment of drug-resistant TB using 6-month regimens
- the 6-month bedaquiline, pretomanid, linezolid and moxifloxacin (BPaLM) regimen;
- the 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine (BDLLfxC) regimen
- Treatment of drug-resistant TB using 9-month regimens
- the 9-month all-oral regimens;
- the modified 9-month all-oral regimens;
- Treatment of drug-resistant TB using longer regimens;
- Treatment of rifampicin-susceptible and isoniazid-resistant TB (Hr-TB);
- Monitoring of the patient response to MDR/RR-TB treatment;
- Starting Antiretroviral therapy (ART) for people on MDR/RR-TB regimen;
- Surgery for people on MDR/RR-TB treatment;
- Hepatitis C virus (HCV) and MDR/RR-TB treatment co-administration.
Each section starts with the current WHO recommendations for that aspect, then gives information on the evidence used to inform that recommendation; a summary of the analyses that were carried out based on the evidence; considerations for specific subgroups; and considerations for implementation, and monitoring and evaluation. Research gaps identified for each of the sections are then presented. Annexes provide more details on the methods, the Guideline Development Groups (GDGs), PICO questions, evidence profiles and evidence-to-decision (EtD) analyses, unpublished data and statistical analysis plans. Additional information on the management of MDR/RR-TB is presented in the relevant chapter of the WHO operational handbook on tuberculosis treatment and care, a separate document that is designed to aid implementation efforts (7, 8). The detailed recommendations presented here replace all of those in previous WHO guidelines on the treatment of DR-TB.